Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Change in Accured Expenses (2019 - 2025)

IDEAYA Biosciences' Change in Accured Expenses history spans 7 years, with the latest figure at -$4.8 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 311.04% year-over-year to -$4.8 million; the TTM value through Dec 2025 reached $10.4 million, down 3.4%, while the annual FY2025 figure was $10.4 million, 3.4% down from the prior year.
  • Change in Accured Expenses for Q4 2025 was -$4.8 million at IDEAYA Biosciences, down from $7.5 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $7.5 million in Q3 2025 and bottomed at -$4.8 million in Q4 2025.
  • The 5-year median for Change in Accured Expenses is $2.1 million (2021), against an average of $1.6 million.
  • The largest YoY upside for Change in Accured Expenses was 668.11% in 2023 against a maximum downside of 399.29% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $476000.0 in 2021, then tumbled by 32.14% to $323000.0 in 2022, then soared by 668.11% to $2.5 million in 2023, then dropped by 8.34% to $2.3 million in 2024, then crashed by 311.04% to -$4.8 million in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Change in Accured Expenses are -$4.8 million (Q4 2025), $7.5 million (Q3 2025), and $4.8 million (Q2 2025).